InvestorsHub Logo
Followers 271
Posts 15407
Boards Moderated 1
Alias Born 03/28/2013

Re: powerwalker post# 71678

Sunday, 07/31/2016 10:23:42 AM

Sunday, July 31, 2016 10:23:42 AM

Post# of 460609
I agree
Anavex alone has great potential
*cough don't forget 3-71 cough*
We shouldn't
as investors
be so focused on one indication (or one compound for that matter) !

We,
investors and management,
are just now beginning to understand what we have here

Initial data is promising. FACT
So
Cautious optimism is where I will remain
until the science proves failure

ACTUALLY PROVES FAILURE
failing a made up short term unrealistic expectation is not failure folks

Anavex has much going for it

I believe we will soon
see further, possibly even more encouraging, developments with other indications

New clinical trial? New indication?
Anavex + Cannabinoids ?
Would be great! wink

“With Anavex drug candidates targeting the sigma-1 receptor, and with the mechanism of action being further validated, we are even more encouraged to advance our studies with additional neurodegenerative diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The Company is intrigued to realize the direct link to the body’s endocannabinoid system and to proceed with potential studies with our sigma-1 drugs candidates and cannabinoids.”

“Our work with the sigma-1 receptor has uncovered relevant aspects of its function in the neuronal plasma membrane as regulator of G protein-coupled receptor (GPCR)-NMDAR cross-regulation. From this point, our research can advance into neuropathic pain, mental illnesses and also certain neurodegenerative diseases in which their genesis or progression requires an altered NMDAR function,” said Dr. Javier Garzon, lead researcher of the paper.

The report, entitled “The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases,” was authored by Dr. Javier Garzon and colleagues from Neuropharmacology, Cajal Institute, CSIC in Madrid, Spain and Drug Discovery and Preclinical Development, Esteve, Barcelona, Spain.

---

Again
I believe Anavex will work best as an early treatment/preventative for various indications

Sentiment was HIGH

But NOW
Anavex Investors are ripping each other apart
Sentiment is LOW
Trust is broken
on many fronts...
Hubris has fallen

The reasons above are why I decided to buy trading shares last Friday

Volatility can be a sign of health but, putting that discussion aside, the overall trend is staying in tact...
slow rise,
with the 3-4$ range continuing to show support in 2016 at,
what many don't realize,
are levels up 300% since 2015

Don't hold unrealistic expectations !
Disappointment must not distract from the true potential

The people can/will/want/need to play games...
The science will remain a non zero sum game big smile
Follow the science
Trade the drama at your own risk

$AVXL

Patience And
Perspective



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News